Li HW 2004.

Methods	Country: China Setting: hospital based Aim: to study the effects of Ziyin Bushen Zhuanggu prescription in the treatment of postmenopausal osteoporosis Study design: randomised controlled trial Analysis: T‐test, Chi2 test Loss to follow‐up: not reported
Participants	Ethnicity: Chinese 45 postmenopausal osteoporosis patients enrolled: 25 in trial group, 20 in control group Inclusion criteria: international diagnostic criteria for osteoporosis, BMD detected by DXA Exclusion criteria: endocrine diseases, etc
Interventions	Experimental: Ziyin Bushen Zhuanggu prescription (1 dose per day), Caltrate (1.2 g, twice a day) and miacalcin (50 IU, injection, twice per week), for 8 months Control: Caltrate (1.2 g, twice a day) and miacalcin (50 IU, injection, twice a week), for 8 months
Outcomes	BMD, E2
Notes	No funding sources or declarations of interest for the primary researchers reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation	Low risk	Random numbers
Allocation concealment	Unclear risk	No information provided
Blinding All outcomes	Unclear risk	Insufficient information to permit judgement of 'low risk' or 'high risk'
Incomplete outcome data addressed All outcomes	Low risk	No missing outcome data
Free of selective reporting	Unclear risk	Not all the outcomes that were of interest in this review were reported
Free of other bias	Low risk	The study appears to be free of other sources of bias